NIAID trial enrolling hospital patients in remdesivir combination therapies
Over the next several months, the National Institute of Allergy and Infectious Diseases expects to enroll up to 1,500 adult COVID-19 hospital patients who require supplemental oxygen in a global clinical trial that aims to determine whether baricitinib or dexamethasone is more effective at preventing mechanical ventilation or death when administered with remdesivir. One group of participants will receive dexamethasone and remdesivir, and another group will receive remdesivir and baricitinib.
Related News Articles
Headline
The AHA provided recommendations to the Food and Drug Administration Dec. 1 in response to a request for information on the measurement and evaluation of…
Headline
The Food and Drug Administration has identified a Class I recall of Baxter Life2000 Ventilation Systems due to a cybersecurity issue discovered through…
Headline
Flu cases are growing or likely growing in 39 states, according to the latest Centers for Disease Control and Prevention data from Nov. 11. COVID-19…
Headline
The Food and Drug Administration yesterday published an announcement from Otsuka ICU Medical saying that the company issued a voluntary recall for a mislabeled…
Headline
A study published Oct. 30 by the American Heart Association found that people have an elevated risk of heart attack and stroke following flu and COVID-19…
Headline
The Centers for Disease Control and Prevention will update its immunization schedules for the COVID-19 and chickenpox vaccines to adopt recent recommendations…